Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
Novo Nordisk (NVO) closed the most recent trading day at $58.33, moving +0.43% from the previous trading session.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (April 2025)
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).
Novo Nordisk: A Price Too Low To Ignore
Weight loss leader Novo Nordisk has had a poor performance at the stock markets year-to-date [YTD] even as the healthcare sector is among the least impacted ones. The key reason for this is disappointing results for its drug trials, though challenges like potential tariffs on Denmark, its home country, also play a part. Yet, the company's robust fundamentals, healthy outlook and attractive market multiples go in its favour, justifying a Buy rating.
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.
Here's Why Novo Nordisk (NVO) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novo Nordisk to invest $1.09 billion to increase production in Brazil
Novo Nordisk , the producer of Ozempic and other medications, announced on Monday a 6.4 billion reais ($1.09 billion) investment in Brazil to boost production.
NVO & LLY Shares Down on Exclusion of Obesity Drugs From Medicare
CMS keeps out LLY and NVO's obesity drugs from Medicare coverage. Medicare, at present, does not cover obesity drugs if they are solely prescribed for weight loss.
Novo Nordisk's head of commercial strategy steps down
Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the Danish drugmaker said on Thursday.
Coffers swelling on Wegovy sales, Novo Holdings doubles income and returns in 2024
Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk , nearly doubled annual income and investment returns to a record 8 billion euros ($8.66 billion) in 2024, it said on Wednesday.
Novo Nordisk: Finally A Buying Opportunity
Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results but remains strong in diabetes treatment, insulin, and GLP-1 products. I outline the bull case for NVO, why their addressed market and market position are still looking phenomenal. I look at fundamental valuation and technical analysis.
